Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Nikki Glaser returns as host of the 2026 Golden Globes: Everything the comedian has said about the upcoming awards show07.01.2026 - 2Federal judge upholds Hawaii's new climate change tax on cruise passengers24.12.2025
- 3Aluminum salts emerge as likely target as health officials scrutinize childhood vaccines26.12.2025
- 4Wedding trip Objections in the US01.01.1
- 5Protest inspired by 'Gen Z' movement draws few young people in Mexico and many government critics15.11.2025
- Solid Living Tips: Experiences from a Wellness Fan
- Email Promoting Instruments for Compelling Efforts
- 'Backward and upward and tilted': Spaceflight causes astronauts' brains to shift inside their skulls
- Authentic Urban areas: Rich Legacy and Lively Societies
- $2,000 tariff rebate checks? 50-year mortgages? Making sense of Trump's new 'affordability' proposals.
- The most effective method to Shake Hands Expertly: A Bit by bit Guide
- Forum Dvorah demands clear support for women in combat as IDF gender debate escalates
- Vote In favor of Your Favored Pet Consideration Administration
- Banks for High Fixed Store Rates: Amplify Your Reserve funds
